| Andrea Scharfe Nugent, MD | |
|
1181 First Colonial Rd, Suite 200, Virginia Beach, VA 23454-2437 | |
| (757) 425-1600 | |
| (757) 425-6495 |
| Full Name | Andrea Scharfe Nugent |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 21 Years |
| Location | 1181 First Colonial Rd, Virginia Beach, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801200621 | NPI | - | NPPES |
| 1801200621 | Other | VA | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0101256427 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-atlantic Womens Care Plc | 8820998156 | 140 |
News Archive
Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy; antibiotics; the search for new remedies against bacterial infections is in high gear.
Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S.
In vitro toxicity testing is rapidly being adopted in the pharmaceutical, chemical, and cosmetics industries, for example, as an alternative to animal studies to predict adverse health effects of drugs and personal care products and the health consequences of environmental exposures.
› Verified 3 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20040115000607 |
News Archive
Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy; antibiotics; the search for new remedies against bacterial infections is in high gear.
Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S.
In vitro toxicity testing is rapidly being adopted in the pharmaceutical, chemical, and cosmetics industries, for example, as an alternative to animal studies to predict adverse health effects of drugs and personal care products and the health consequences of environmental exposures.
› Verified 3 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Mammography Center |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20080611000246 |
News Archive
Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy; antibiotics; the search for new remedies against bacterial infections is in high gear.
Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S.
In vitro toxicity testing is rapidly being adopted in the pharmaceutical, chemical, and cosmetics industries, for example, as an alternative to animal studies to predict adverse health effects of drugs and personal care products and the health consequences of environmental exposures.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrea Scharfe Nugent, MD 1181 First Colonial Rd, Suite 200, Virginia Beach, VA 23454-2437 Ph: (757) 425-1600 | Andrea Scharfe Nugent, MD 1181 First Colonial Rd, Suite 200, Virginia Beach, VA 23454-2437 Ph: (757) 425-1600 |
News Archive
Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy; antibiotics; the search for new remedies against bacterial infections is in high gear.
Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S.
In vitro toxicity testing is rapidly being adopted in the pharmaceutical, chemical, and cosmetics industries, for example, as an alternative to animal studies to predict adverse health effects of drugs and personal care products and the health consequences of environmental exposures.
› Verified 3 days ago
Colleen M Connor, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 828 Healthy Way, Suite 330, Virginia Beach, VA 23462 Phone: 757-461-3890 Fax: 757-467-0301 | |
George Marshall Kemp, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1120 First Colonial Rd, Suite 202, Virginia Beach, VA 23454 Phone: 757-481-0327 Fax: 757-481-6731 | |
Donald Bell, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1080 First Colonial Rd, Suite 300, Virginia Beach, VA 23454 Phone: 757-481-7222 Fax: 757-496-3772 | |
Sarah Elizabeth Murphy, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 828 Healthy Way Ste 330, Virginia Beach, VA 23462 Phone: 757-461-3890 | |
Janice Tracy Levin, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1080 First Colonial Rd, Suite 300, Virginia Beach, VA 23454 Phone: 757-481-7222 Fax: 757-496-3772 | |
Amour M Johnson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1080 First Colonial Rd, Suite 300, Virginia Beach, VA 23454 Phone: 757-481-7222 Fax: 757-496-3772 | |
Robin Lynn Poe-zeigler, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 448 Viking Dr, Suite 100, Virginia Beach, VA 23452 Phone: 757-496-5370 Fax: 757-481-3354 |